

**EIF2A Antibody (C-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP13720b****Specification**

---

**EIF2A Antibody (C-term) Blocking peptide - Product Information**Primary Accession [Q9BY44](#)**EIF2A Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 83939**Other Names**

Eukaryotic translation initiation factor 2A, eIF-2A, 65 kDa eukaryotic translation initiation factor 2A, Eukaryotic translation initiation factor 2A, N-terminally processed, EIF2A

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody AP13720b was selected from the C-term region of EIF2A. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**EIF2A Antibody (C-term) Blocking peptide - Protein Information****Name** EIF2A**Function**

Functions in the early steps of protein synthesis of a small number of specific mRNAs. Acts by directing the binding of methionyl- tRNA<sub>i</sub> to 40S ribosomal subunits. In contrast to the eIF-2 complex, it binds methionyl-tRNA<sub>i</sub> to 40S subunits in a codon-dependent manner, whereas the eIF-2 complex binds methionyl-tRNA<sub>i</sub> to 40S subunits in a GTP-dependent manner.

**Tissue Location**

Widely expressed. Expressed at higher level in pancreas, heart, brain and placenta.

**EIF2A Antibody (C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

#### **EIF2A Antibody (C-term) Blocking peptide - Images**

#### **EIF2A Antibody (C-term) Blocking peptide - Background**

EIF2A is a 65-kD protein that catalyzes the formation of puromycin-sensitive 80S preinitiation complexes (Zoll et al., 2002[PubMed 12133843]).

#### **EIF2A Antibody (C-term) Blocking peptide - References**

Groskreutz, D.J., et al. J. Biol. Chem. 285(31):24023-24031(2010) Bailey, S.D., et al. Diabetes Care (2010) In press :Willis, K.L., et al. Virology 394(1):73-81(2009) Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009) Spurgeon, M.E., et al. J. Virol. 83(19):9970-9982(2009)